Item 7.01 Regulation FD Disclosure.
Attached as Exhibit 99.1 hereto and incorporated
into this Item 7.01 by reference is the Analyst Day presentation that LumiraDx Limited (“LumiraDx”) has prepared for use in
connection with its Analyst Day, scheduled for July 16, 2021, relating to the proposed business combination of LumiraDx and CA Healthcare
Acquisition Corp. (“CAH”). The foregoing (including the information presented in Exhibit 99.1) is being furnished pursuant
to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act. The submission of the information set forth in this Item
7.01 will not be deemed an admission as to the materiality of any information in this Item 7.01, including the information presented in
Exhibit 99.1, which is provided solely in connection with Regulation FD.
Additional information
In connection with the
proposed business combination, LumiraDx has filed with the Securities and Exchange Commission (“SEC”) a registration Statement
on Form F-4 in connection with the proposed business combination (the “Registration Statement”) containing a preliminary proxy
statement of CAH and a preliminary prospectus of LumiraDx, and after the Registration Statement is declared effective, CAH will mail a
definitive proxy statement/prospectus relating to the proposed business combination to its shareholders. This Current Report on Form 8-K
does not contain all the information that should be considered concerning the proposed business combination and is not intended to form
the basis of any investment decision or any other decision in respect of the business combination. CAH’s shareholders and other
interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the
definitive proxy statement/prospectus and other documents filed in connection with the proposed business combination, as these materials
will contain important information about LumiraDx, CAH and the proposed business combination. When available, the definitive proxy statement/prospectus
and other relevant materials for the proposed business combination will be mailed to shareholders of CAH as of a record date to be established
for voting on the proposed business combination. Such shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus,
the definitive proxy statement/prospectus and other documents filed with the SEC, without charge, once available, at the SEC’s website
at www.sec.gov, or by directing a request to CA Healthcare Acquisition Corp., 99 Summer Street, Suite 200 Boston, MA 02110.
Participants in Solicitation
CAH and its directors
and executive officers may be deemed participants in the solicitation of proxies from CAH’s shareholders with respect to the
proposed business combination. A list of the names of those directors and executive officers and a description of their interests in
CAH is contained in the Registration Statement. Additional information regarding the interests of such participants will
be contained in the proxy statement/prospectus for the proposed business combination when available.
LumiraDx and its
directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of CAH
in connection with the proposed business combination. A list of the names of such directors and executive officers and information
regarding their interests in the proposed business combination is contained in the Registration Statement. Additional information
regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed business
combination when available.
Forward-Looking Statements
Certain statements in
this Current Report on Form 8-K may be considered “forward-looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally
relate to future events or CAH’s or LumiraDx’s future financial or operating performance. For example, projections of
future sales and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as “may,” “should,” “expect,” “intend,” “will,”
“estimate,” “anticipate,” “believe,” “predict” or the negatives of these terms or
variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors
which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These
forward-looking statements are based upon estimates and assumptions that, while considered reasonable by CAH and its management, and
LumiraDx and its management, as the case may be, are inherently uncertain factors that may cause actual results to differ materially
from current expectations include, but are not limited to: 1) the occurrence of any event, change or other circumstances that could
give rise to the termination of the Agreement and Plan of Merger between LumiraDx and CAH; 2) the outcome of any legal proceedings
that may be instituted against CAH, the combined company or others following the announcement of the business combination and any
definitive agreements with respect thereto; 3) the inability to complete the business combination due to the failure to obtain
approval of the shareholders of CAH or to satisfy other conditions to closing; 4) changes to the proposed structure of the business
combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining
regulatory approval of the business combination; 5) the ability to meet the Nasdaq’s listing standards following the
consummation of the business combination; 6) the risk that the business combination disrupts current plans and operations of
LumiraDx as a result of the announcement and consummation of the business combination; 7) the ability to recognize the anticipated
benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company
to grow and manage growth profitably, maintain relationships with customers, manufacturers and suppliers and retain its management
and key employees; 8) costs related to the business combination; 9) changes in applicable laws or regulations; 10) the possibility
that LumiraDx or the combined company may be adversely affected by other economic, business and/or competitive factors; 11)
LumiraDx’s estimates of its financial performance; and 12) other risks and uncertainties set forth in the section entitled
“Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in CAH’s Registration
Statement on form S-1 filed with the SEC on January 8, 2021 and the proxy statement/prospectus discussed above. Nothing in this
Current Report on Form 8-K should be regarded as a representation by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such forward looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as of the date they are made. Neither CAH nor LumiraDx undertakes any
duty to update these forward-looking statements, except as otherwise required by law.